Device Trial Radar · NCT04203667
EndoRotor® Endoscopic Mucosal Resection System for the Colon
Last checked: Nov 20, 2026Latest source record: Apr 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Apr 18, 2018
Primary completion
Apr 5, 2020
Study completion Apr 5, 2020
Sponsor
- Lead sponsor
- Interscope, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 18, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The EndoRotor® is intended for use (USA labeling) in endoscopic procedures by a trained gastroenterologist to resect and remove tissue, not intended for biopsy, of the gastrointestinal (GI) system including post-endoscopic mucosal resection (EMR) tissue persistence with a scarred base and residual tissue from the peripheral margins following EMR. In this trial investigators will conduct a post-market, prospective, non-randomized, multi-center study for the treatment of subjects with the need for resection of recurrent flat or sessile colorectal lesions where EndoRotor is the primary resection modality of persistent adenoma with a scarred base.
Conditions
- Polyp of Colon
- Endoscopic Mucosal Resection
- Recurrent Colon Adenoma
Interventions
EndoRotor ResectionDevice
The EndoRotor® is a powered cutting cannula for the removal of alimentary tract mucosa. Cutting is performed by aspirating tissue into a rotating cutting window. The resected tissue is immediately aspirated away from the resection site and collected in the EndoRotor Specimen Trap. The tissue can then be sent for pathological examination using standard methods. The system consists of a power console, foot control, specimen trap with pre-loaded filter and the applied part, which is the single-use catheter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness Endpoint Defined as the Ability of the EndoRotor to Resect Lesions Without Concomitant Use of Other Resection Modalities and With no Device-related Serious Adverse Events Through the 90 Day Post Procedure Follow-up Visit.Time frame: Index Procedure through 90 Day Post Procedure Follow-up Visit
- Primary Safety Analysis Defined as the Occurrence of Serious Adverse Events Related to the EndoRotor Device as Measured From the Index Procedure Through the 90 Day Post Procedure Follow-up Visit.Time frame: Index Procedure through 90 Day Post Procedure Follow-up Visit
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Geisinger Medical Center
Danville, Pennsylvania
Centre Hospitalier Universitaire (CHU)
Angers, France
Hopital Edouard Herriot
Lyon, France
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.